drugset / Trial / NCT05488132
Administration of Anti-siglec-6 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the safety and efficacy of anti-Siglec-6 CAR-T cells in the treatment of relapsed and refractory acute myeloid leukemia.
Timeline
- Start
- 2022-04-01
- Primary completion
- 2024-03-31
- Completion
- 2025-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | anti-siglec-6 CAR-T cell therapy | Cell therapy | — | — |